Imunon Q1 net loss $4.1M; cash only through late Q2 2025; Phase 3 ovarian cancer trial initiated

Imunon, Inc.

2025-Q1 EPS reported -$0.28

Net loss $4.1M ($0.28 per share) vs $4.9M ($0.52 per share) in Q1 2024; operating expenses down 18%.
Cash and equivalents $2.9M as of 2025-03-31; company expects funding into late Q2 2025 only.
First trial site initiated for Phase 3 OVATION 3 study of IMNN-001 in advanced ovarian cancer.
Abstract for OVATION 2 updated survival analysis accepted for oral presentation at 2025 ASCO Annual Meeting.
Appointed Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer effective 2025-02-18.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.